The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NRCID     (13S,17S)-17-ethynyl-17- hydroxy-13-methyl...

Synonyms: NDR
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of norethindrone


High impact information on norethindrone


Chemical compound and disease context of norethindrone


Biological context of norethindrone


Anatomical context of norethindrone


Associations of norethindrone with other chemical compounds


Gene context of norethindrone


Analytical, diagnostic and therapeutic context of norethindrone


  1. Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Jeng, M.H., Jordan, V.C. Mol. Endocrinol. (1991) [Pubmed]
  2. Pretreatment with low doses of norethindrone potentiates the osteogenic effects of fluoride on human osteosarcoma cells. Takada, J., Baylink, D.J., Lau, K.H. J. Bone Miner. Res. (1995) [Pubmed]
  3. Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption. Lau, K.H., Wang, S.P., Linkhart, T.A., Demarest, K.T., Baylink, D.J. J. Bone Miner. Res. (1994) [Pubmed]
  4. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. Surrey, E.S., Judd, H.L. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  5. Norethindrone inhibition of testosterone secretion by an ovarian Sertoli-Leydig cell tumor. Brumsted, J.R., Chapitis, J., Riddick, D., Gibson, M. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  6. Norethindrone scatters silver-stained nucleolar organizer regions of Ishikawa cells. Yokoyama, Y., Niwa, K., Tamaya, T. Cancer Res. (1991) [Pubmed]
  7. Treatment of postmenopausal hyperparathyroidism with norethindrone. Long-term effects on forearm mineral content. Wishart, J., Horowitz, M., Need, A., Chatterton, B., Nordin, B.E. Arch. Intern. Med. (1990) [Pubmed]
  8. Role of reactive oxygen in synthetic estrogen induction of hepatocellular carcinomas in rats and preventive effect of vitamins. Ogawa, T., Higashi, S., Kawarada, Y., Mizumoto, R. Carcinogenesis (1995) [Pubmed]
  9. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Farley, T.M., Meirik, O., Collins, J. Hum. Reprod. Update (1999) [Pubmed]
  10. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Björn, I., Bixo, M., Nöjd, K.S., Nyberg, S., Bäckström, T. Am. J. Obstet. Gynecol. (2000) [Pubmed]
  11. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Surrey, E.S., Voigt, B., Fournet, N., Judd, H.L. Fertil. Steril. (1995) [Pubmed]
  12. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Trapnell, C.B., Donahue, S.R., Collins, J.M., Flockhart, D.A., Thacker, D., Abernethy, D.R. Clin. Pharmacol. Ther. (1998) [Pubmed]
  13. Inhibition of hepatic drug metabolism by norethindrone. Field, B., Lu, C., Hepner, G.W. Clin. Pharmacol. Ther. (1979) [Pubmed]
  14. Mutual modification of glucose-stimulated serum insulin responses in female rhesus monkeys by ethinyl estradiol and nortestosterone derivatives. Beck, P., Venable, R.L., Hoff, D.L. J. Clin. Endocrinol. Metab. (1975) [Pubmed]
  15. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing. Back, D.J., Breckenridge, A.M., Crawford, F.E., Mciver, M., Orme, M.L., Park, B.K., Rowe, P.H., Smith, E. Clin. Pharmacol. Ther. (1978) [Pubmed]
  16. Aromatization of norethindrone to ethinyl estradiol by human placental microsomes. Barbieri, R.L., Petro, Z., Canick, J.A., Ryan, K.J. J. Clin. Endocrinol. Metab. (1983) [Pubmed]
  17. Unscheduled DNA synthesis caused by norethindrone and related contraceptive steroids in short-term male rat hepatocyte cultures. Blakey, D.C., White, I.N. Carcinogenesis (1985) [Pubmed]
  18. Factors responsible for the formation of different N-alkylated porphyrins in rat liver microsomal systems exposed to norethindrone. The role of 3 alpha-hydroxysteroid dehydrogenase. White, I.N., Blakey, D.C., Green, M.L., Jarman, M., Schulten, H.R. Biochem. J. (1986) [Pubmed]
  19. Secondary hyperparathyroidism caused by oral contraceptives. Moses, A.M., Notman, D.D. Arch. Intern. Med. (1982) [Pubmed]
  20. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. Carr, B.R., Parker, C.R., Madden, J.D., MacDonald, P.C., Porter, J.C. J. Clin. Endocrinol. Metab. (1979) [Pubmed]
  21. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Eldon, M.A., Underwood, B.A., Randinitis, E.J., Sedman, A.J. Neurology (1998) [Pubmed]
  22. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Heald, A., Selby, P.L., White, A., Gibson, J.M. Am. J. Obstet. Gynecol. (2000) [Pubmed]
  23. Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Gallmeier, E., Winter, J.M., Cunningham, S.C., Kahn, S.R., Kern, S.E. Carcinogenesis (2005) [Pubmed]
  24. Species differences in the hepatic formation of green pigments following the administration of norethindrone. White, I.N., Boobis, A.R., Davies, D.S. Biochem. Pharmacol. (1984) [Pubmed]
  25. Destruction of cytochrome P-450 and formation of green pigments by contraceptive steroids in rat hepatocyte suspensions. Blakey, D.C., White, I.N. Biochem. Pharmacol. (1986) [Pubmed]
  26. An investigation of the effects of phenobarbitone on the pharmacokinetics of norethindrone in the rat using liver perfusion and everted gut sacs. Back, D.J., Macnee, C.M., Orme, M.L., Rowe, P.H., Smith, E. Biochem. Pharmacol. (1984) [Pubmed]
  27. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres: phase II clinical study. Singh, M., Saxena, B.B., Graver, R., Ledger, W.J. Fertil. Steril. (1989) [Pubmed]
WikiGenes - Universities